Cite
HARVARD Citation
Sanga, M. et al. (2017). An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia*. Xenobiotica. pp. 856-869. [Online].